Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called spinocerebellar ataxia. Read more here.

Biohaven Pharmaceutical BHVN and Pfizer PFE announced a definitive agreement wherein the latter will acquire the former for $148.50 per share or an aggregate equity value of $11.6 billion.

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors ...

In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.47 per share. By comparison ...

Investors in Biohaven Pharmaceutical Holding Co Ltd (Symbol: BHVN) saw new options become available this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has ...

Biohaven (NYSE:BHVN) just reported results for the first quarter of 2024. Biohaven reported earnings per share of -$1.77. This was below the analyst estimate for EPS of -$1.57. The company did not ...